Trial Profile
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Oct 2023
Price :
$35
*
At a glance
- Drugs Tenapanor (Primary)
- Indications Irritable bowel syndrome
- Focus Registrational; Therapeutic Use
- Acronyms T3MPO-1
- Sponsors Ardelyx
- 23 Oct 2023 According to Ardelyx media release, data from this study presented at the American College of Gastroenterology (ACG) annual meeting,
- 23 Oct 2023 Results published in the Ardelyx Media Release
- 11 Sep 2023 According to an Ardelyx media release, post-hoc pooled results from T3MPO-1 and T3MPO-2 trials were presented at the 2023 Gastroenterology & Hepatology Advanced Practice Providers (GHAPP) Annual Conference currently being held in National Harbor, Maryland September 7-9.